Dorsey Wright & Associates Sells 7,975 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

Dorsey Wright & Associates reduced its stake in shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Free Report) by 10.1% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 70,671 shares of the company's stock after selling 7,975 shares during the period. Verona Pharma PLC American Depositary Share comprises 1.1% of Dorsey Wright & Associates' investment portfolio, making the stock its 28th biggest position. Dorsey Wright & Associates owned approximately 0.09% of Verona Pharma PLC American Depositary Share worth $4,487,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of VRNA. Wellington Management Group LLP grew its holdings in Verona Pharma PLC American Depositary Share by 61.0% during the fourth quarter. Wellington Management Group LLP now owns 3,025,241 shares of the company's stock valued at $140,492,000 after purchasing an additional 1,146,609 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Verona Pharma PLC American Depositary Share by 37.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,833,532 shares of the company's stock worth $85,150,000 after acquiring an additional 498,338 shares during the period. RTW Investments LP purchased a new stake in Verona Pharma PLC American Depositary Share in the 4th quarter worth about $84,568,000. Janus Henderson Group PLC raised its stake in Verona Pharma PLC American Depositary Share by 59.9% in the 4th quarter. Janus Henderson Group PLC now owns 1,667,165 shares of the company's stock valued at $77,466,000 after acquiring an additional 624,370 shares during the period. Finally, Hood River Capital Management LLC lifted its holdings in Verona Pharma PLC American Depositary Share by 3.6% during the fourth quarter. Hood River Capital Management LLC now owns 1,485,256 shares of the company's stock valued at $68,975,000 after purchasing an additional 51,322 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company's stock.

Verona Pharma PLC American Depositary Share Price Performance

Shares of Verona Pharma PLC American Depositary Share stock traded up $0.05 on Thursday, hitting $105.00. 2,640,833 shares of the company traded hands, compared to its average volume of 7,544,692. Verona Pharma PLC American Depositary Share has a 12-month low of $18.51 and a 12-month high of $105.30. The company has a current ratio of 8.86, a quick ratio of 8.73 and a debt-to-equity ratio of 1.07. The company has a market cap of $8.94 billion, a P/E ratio of -52.50 and a beta of 0.24. The firm's 50-day simple moving average is $90.51 and its 200 day simple moving average is $71.30.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.49. The firm had revenue of $98.65 million for the quarter, compared to the consensus estimate of $41.47 million. Analysts expect that Verona Pharma PLC American Depositary Share will post -1.95 earnings per share for the current fiscal year.

Analyst Ratings Changes

VRNA has been the topic of several research reports. Cowen lowered shares of Verona Pharma PLC American Depositary Share from a "buy" rating to a "hold" rating in a research report on Wednesday, July 9th. HC Wainwright reiterated a "neutral" rating and set a $107.00 price objective (up from $90.00) on shares of Verona Pharma PLC American Depositary Share in a research note on Monday, July 14th. Roth Capital downgraded Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 10th. Canaccord Genuity Group downgraded shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating and set a $107.00 price target on the stock. in a report on Wednesday, July 9th. Finally, BTIG Research cut shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 10th. Eleven equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, Verona Pharma PLC American Depositary Share currently has a consensus rating of "Hold" and a consensus price target of $109.00.

Insider Buying and Selling at Verona Pharma PLC American Depositary Share

In other news, insider Kathleen A. Rickard sold 114,984 shares of the business's stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $8.82, for a total value of $1,014,158.88. Following the completion of the sale, the insider owned 2,546,472 shares of the company's stock, valued at approximately $22,459,883.04. The trade was a 4.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Mark W. Hahn sold 400,000 shares of the stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $11.40, for a total value of $4,560,000.00. Following the sale, the chief financial officer owned 12,278,992 shares of the company's stock, valued at $139,980,508.80. This represents a 3.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,965,800 shares of company stock valued at $20,056,881. Company insiders own 4.80% of the company's stock.

Verona Pharma PLC American Depositary Share Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.